Author correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy.
Wei, Andrew H Panayiotidis, Panayiotis Montesinos, Pau Laribi, Kamel Ivanov, Vladimir Kim, Inho Novak, Jan Stevens, Don A Fiedler, Walter Pagoni, Maria
Wei, Andrew H
Panayiotidis, Panayiotis
Montesinos, Pau
Laribi, Kamel
Ivanov, Vladimir
Kim, Inho
Novak, Jan
Stevens, Don A
Fiedler, Walter
Pagoni, Maria
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2021-10-26
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
No abstract available
Citation
Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Stevens DA, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Chyla B, Sun Y, Jiang Q, Mendes W, Hayslip J, DiNardo CD. Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy. Blood Cancer J. 2021 Oct 26;11(10):171. doi: 10.1038/s41408-021-00565-6. Erratum for: Blood Cancer J. 2021 Oct 1;11(10):163
Type
Corrigendum